Advertisement

Topics

Angion Biomedica Corp. Company Profile

00:30 EST 23rd November 2017 | BioPortfolio

Angion Biomedica is a biopharmaceutical company founded in 1998 focused on discovery and development of drugs that harness the body’s protective, reparative and regenerative systems toward therapeutic benefit. The Company’s fully integrated, multidisciplinary research and development facility is located in Garden City, New York. The Company’s drug discovery and development platform utilizes state-of-the-art, fully-integrated molecular modeling, medicinal chemistry and preclinical biology capabilities to identify and optimize molecular drug candidates. Angion Biomedica’s efforts have yielded a rich and diverse clinical and preclinical pipeline comprising novel HGF and other kinase modulators, PARP-1 inhibitors and retinoic acid signaling modulators. Issued and pending U.S and international patents allow Angion Biomedica to retain worldwide rights to its proprietary molecules and uses for clinical benefit. Please obtain further information at www.angion.com or contact Angion Biomedica at mail@angion.com


News Articles [73 Associated News Articles listed on BioPortfolio]

Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.

Angion Biomedica Corp Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAngion Biomedica Corp Angion discovers and develops novel treatments for acute and chronic organ injury and disease. The company's portfolio of pipeline compounds includes BB3, ANG3070, ANG3586...

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrate...

Oxford BioMedica inks $100 million supply agreement

Oxford BioMedica has signed an agreement for the commercial and clinical supply of lentiviral vectors…

Oxford BioMedica (OXB) - Kymriah approved - royalties to OXB assured

Edison Investment Research - Pharmaceutical & healthcare - Oxford BioMedica: Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been ...

Oxford BioMedica secures commercial supply licence from UK MHRA

Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material...

Oxford BioMedica signs $100m CAR-T deal with Novartis

Oxford BioMedica has signed a deal worth up to $100m with Novartis to supply modified viruses used to generate its CAR-T therapies. The deal represents a major financial boost for the UK biotech fir...

Oxford BioMedica could get $100m following CAR-T approval

UK biotech Oxford BioMedica could earn more than $100 million from Novartis for providing a key component in the recently approved CAR-T cancer cell therapy. The FDA this week approved Novartis’ c...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules

The ex-vivo lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross sec...

Companies [49 Associated Companies listed on BioPortfolio]

Angion Biomedica Corp.

Angion Biomedica is a biopharmaceutical company founded in 1998 focused on discovery and development of drugs that harness the body’s protective, reparative and regenerative ...

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Acolyte Biomedica Ltd

Acolyte Biomedica Ltd provides rapid diagnostic systems for clinical microbiology. Acolyte's BacLite® platform allows microbial detection in hours instead of days, improving laboratory workflow, redu...

BioMedica Diagnostics Inc.

BioMedica Diagnostics Inc. is a Canadian Medical Devices Company with a dedicated focus on providing Affordable Medical Diagnostic Solutions.The primary targets for our products are the emerging econo...

More Information about "Angion Biomedica Corp." on BioPortfolio

We have published hundreds of Angion Biomedica Corp. news stories on BioPortfolio along with dozens of Angion Biomedica Corp. Clinical Trials and PubMed Articles about Angion Biomedica Corp. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Angion Biomedica Corp. Companies in our database. You can also find out about relevant Angion Biomedica Corp. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record